Article Text

A1 New starts and directions: understanding the role of hidden expansion proteins in HD
  1. Monica Bañez-Coronel1,2,
  2. Fatma Ayhan1,2,
  3. Alex D Tarabochia1,2,
  4. Tao Zu1,2,
  5. Barbara A Perez1,2,
  6. Solaleh Khoramian Tusi1,2,6,
  7. Olga Pletnikova7,
  8. David R Borchelt1,4,
  9. Christopher A Ross8,9,10,11,12,13,14,
  10. Russell L Margolis8,9,10,12,14,
  11. Anthony T Yachnis5,
  12. Juan C Troncoso7,10,
  13. Laura PW Ranum1,2,3,6
  1. 1Centre for NeuroGenetics
  2. 2Department of Molecular Genetics and Microbiology
  3. 3Department of Neurology
  4. 4Department of Neuroscience
  5. 5Department of Pathology, Immunology and Laboratory Medicine, College of Medicine
  6. 6Genetics Institute, University of Florida, Gainesville, FL, USA
  7. 7Department of Pathology
  8. 8Division of Neurobiology
  9. 9Department of Psychiatry
  10. 10Department of Neurology
  11. 11Department of Pharmacology
  12. 12Department of Neuroscience
  13. 13Program in Cellular and Molecular Medicine
  14. 14Baltimore Huntington’s Disease Centre, The John Hopkins University School of Medicine, Baltimore, MD, USA


Huntington’s disease (HD) is caused by a CAG CTG expansion in the huntingtin (HTT) gene. While most research has focused on the HTT polyGln-expansion protein, we recently reported that four additional, novel, homopolymeric expansion proteins (polyAla, polySer, polyLeu, polyCys) accumulate in HD human brains. These sense and antisense repeat-associated non-ATG (RAN) translation proteins accumulate most abundantly in brain regions with neuronal loss, microglial activation and apoptosis, including caudate/putamen, white matter, and in juvenile-onset cases, also the cerebellum. RAN protein accumulation and aggregation patterns are length-dependent. Codon substitution experiments show HD-RAN proteins are toxic to neural cells independent of RNA effects. These data support an important role for RAN proteins in HD, and suggest that therapeutic strategies targeting both sense and antisense transcripts, RAN proteins or RAN translation may be important for treating HD patients. We are currently using mouse models of HD to understand the time-course and impact that HD-RAN proteins play in disease and also to examine which models best mimic the findings we have seen in human autopsy patients. The discovery of HD RAN proteins was the first demonstration that RAN translation can occur across an expansion located in an open reading frame and suggests RAN translation may also contribute to other polyglutamine diseases. Recent efforts to understand the mechanisms of RAN translation and insights into the roles that RNA gain of function and RAN mechanisms play in HD as well as ALS/FTD, ataxia and myotonic dystrophy will be discussed.

  • RAN translation
  • RAN proteins
  • polyAla
  • polySer
  • polyLeu
  • polyCys

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.